PURPOSE: The aim of this study was to investigate the relationship between (123)I-metaiodobenzylguanidine (MIBG) scan semi-quantification and a new (18)F-DOPA positron emission tomography (PET)/CT score in patients with suspected or documented neuroblastoma (NB) relapse and to assess the association between these two parameters and progression-free survival (PFS)/overall survival (OS). METHODS: We analysed 24 NB patients who had undergone (123)I-MIBG and (18)F-DOPA PET/CT scans at the time of suspected relapse, after applying a proper scoring system for each scan. In time-to-event analyses, the score distributions were regarded as continuous and were categorized in tertiles and medians. We used Kaplan-Meier curves and Cox proportional hazard models for PFS and OS in order to estimate the independent prognostic impact of (123)I-MIBG and (18)F-DOPA PET/CT scans. RESULTS: The (123)I-MIBG and (18)F-DOPA scores were highly and positively correlated (Spearman's rho = 0.8, p < 0.001). Over a median follow-up of 14 months (range 6-82), 12 cases of disease progression and 6 deaths occurred. Multivariate Cox models showed a higher risk of disease progression [hazard ratio (HR) 17.0, 95% confidence interval (CI) 2.7-109] in NB patients with (123)I-MIBG score > 3 (3rd tertile) and an even higher risk (HR:37.2, 95% CI 2.4-574) in those with (18)F-DOPA whole-body metabolic burden (WBMB) >7.5 (median), after adjustment for all main clinical/pathological factors considered. Kaplan-Meier analyses showed a significant association with OS (log-rank p = 0.01 and p = 0.03 for (123)I-MIBG and (18)F-DOPA WBMB, respectively). CONCLUSION: Our results confirm the good agreement between (18)F-DOPA PET/CT and (123)I-MIBG scan in patients affected by NB relapse. In time-to-event analyses, (123)I-MIBG scan and (18)F-DOPA PET/CT scores were independently and significantly associated with disease progression.
PURPOSE: The aim of this study was to investigate the relationship between (123)I-metaiodobenzylguanidine (MIBG) scan semi-quantification and a new (18)F-DOPA positron emission tomography (PET)/CT score in patients with suspected or documented neuroblastoma (NB) relapse and to assess the association between these two parameters and progression-free survival (PFS)/overall survival (OS). METHODS: We analysed 24 NB patients who had undergone (123)I-MIBG and (18)F-DOPA PET/CT scans at the time of suspected relapse, after applying a proper scoring system for each scan. In time-to-event analyses, the score distributions were regarded as continuous and were categorized in tertiles and medians. We used Kaplan-Meier curves and Cox proportional hazard models for PFS and OS in order to estimate the independent prognostic impact of (123)I-MIBG and (18)F-DOPA PET/CT scans. RESULTS: The (123)I-MIBG and (18)F-DOPA scores were highly and positively correlated (Spearman's rho = 0.8, p < 0.001). Over a median follow-up of 14 months (range 6-82), 12 cases of disease progression and 6 deaths occurred. Multivariate Cox models showed a higher risk of disease progression [hazard ratio (HR) 17.0, 95% confidence interval (CI) 2.7-109] in NB patients with (123)I-MIBG score > 3 (3rd tertile) and an even higher risk (HR:37.2, 95% CI 2.4-574) in those with (18)F-DOPA whole-body metabolic burden (WBMB) >7.5 (median), after adjustment for all main clinical/pathological factors considered. Kaplan-Meier analyses showed a significant association with OS (log-rank p = 0.01 and p = 0.03 for (123)I-MIBG and (18)F-DOPAWBMB, respectively). CONCLUSION: Our results confirm the good agreement between (18)F-DOPA PET/CT and (123)I-MIBG scan in patients affected by NB relapse. In time-to-event analyses, (123)I-MIBG scan and (18)F-DOPA PET/CT scores were independently and significantly associated with disease progression.
Authors: Nikolaos D Papathanasiou; Mark N Gaze; Kevin Sullivan; Matthew Aldridge; Wendy Waddington; Ahmad Almuhaideb; Jamshed B Bomanji Journal: J Nucl Med Date: 2011-03-18 Impact factor: 10.057
Authors: K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn Journal: Br J Cancer Date: 2010-04-27 Impact factor: 7.640
Authors: Helle-Brit Fiebrich; Adrienne H Brouwers; Michiel N Kerstens; Milan E J Pijl; Ido P Kema; Johan R de Jong; Pieter L Jager; Philip H Elsinga; Rudi A J O Dierckx; Jacqueline E van der Wal; Wim J Sluiter; Elisabeth G E de Vries; Thera P Links Journal: J Clin Endocrinol Metab Date: 2009-07-21 Impact factor: 5.958
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: Peter E Zage; Morris Kletzel; Kevin Murray; Robert Marcus; Robert Castleberry; Yang Zhang; Wendy B London; Cynthia Kretschmar Journal: Pediatr Blood Cancer Date: 2008-12 Impact factor: 3.167
Authors: Arnoldo Piccardo; Giovanni Morana; Michela Massollo; Marco Pescetto; Massimo Conte; Alberto Garaventa Journal: Nucl Med Mol Imaging Date: 2015-02-03
Authors: Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2018-10 Impact factor: 9.236
Authors: Benjamin Leroy-Freschini; Vincent Amodru; Pietro Addeo; Frédéric Sebag; Michel Vix; Laurent Brunaud; Marc Klein; Thibault Bahougne; Philippe Bachellier; Frédéric Castinetti; Bernard Goichot; Elodie Chevalier; David Taieb; Alessio Imperiale Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-07 Impact factor: 9.236